Hospital
Mobile Infirmary Association
Mobile Infirmary Association was paid $4.59M by Medicaid between Jan 2018 and Nov 2024, across 66 billing codes. Its largest line is 99285, emergency room visit (most serious) — 26% of everything it billed.
33Billing provider infoMOBILE INFIRMARY ASSOCIATION
MOBILE, AL 36607
MOBILE, AL 36607
33aNPI1558364802assigned 05/31/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.59M
24GClaims173,991
24DCodes billed66
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#16 of 77
Median peer was paid$1.13M
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,090 | $506K | |
| 2019 | 23,590 | $378K | |
| 2020 | 13,033 | $317K | |
| 2021 | 22,052 | $673K | |
| 2022 | 33,722 | $1.06M | |
| 2023 | 31,217 | $1.13M | |
| 2024incomplete | 15,287 | $527K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 4,728 | 4,333 | $1.19M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 27,869 | 25,696 | $1.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 16,392 | 15,039 | $987K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.8% | 28,786 | 25,606 | $218K |
| 80053 | Comprehensive metabolic panel | 4.4% | 20,738 | 18,796 | $201K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.3% | 5,156 | 4,739 | $198K |
| 62322 | 2.1% | 1,117 | 652 | $96K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 3,175 | 2,824 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 1,826 | 1,688 | $95K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 6,495 | 5,909 | $66K |
| 83735 | <1% | 6,885 | 6,193 | $43K | |
| 87400 | <1% | 4,742 | 2,213 | $27K |
54 more codes
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,082 | $25K |
| 83690 | <1% | 4,480 | $25K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 604 | $25K |
| 80306 | <1% | 2,574 | $25K | |
| 62323 | <1% | 161 | $23K | |
| 82553 | <1% | 2,025 | $21K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 348 | $19K |
| 84484 | <1% | 2,457 | $18K | |
| 81003 | <1% | 7,061 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,569 | $14K |
| 81001 | <1% | 4,179 | $14K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,545 | $12K |
| 82550 | <1% | 2,141 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,504 | $11K |
| 0001A | <1% | 321 | $11K | |
| 81025 | <1% | 3,252 | $10K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 190 | $10K |
| 86738 | <1% | 497 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 48 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,822 | $8K |
| 83880 | <1% | 375 | $8K | |
| 0002A | <1% | 227 | $8K | |
| 87077 | <1% | 789 | $7K | |
| 87430 | <1% | 346 | $5K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 32 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 224 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 98 | $2K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 188 | $923.80 |
| 80076 | <1% | 146 | $920.32 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 970 | $885.24 |
| 87449 | <1% | 27 | $550.42 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,277 | $362.52 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 177 | $362.17 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 76 | $359.52 |
| 87071 | <1% | 59 | $319.77 | |
| 72110 | <1% | 31 | $159.18 | |
| 73560 | <1% | 31 | $102.42 | |
| 73030 | <1% | 28 | $83.64 | |
| 82962 | <1% | 26 | $64.43 | |
| 72050 | <1% | 15 | $56.58 | |
| 73521 | <1% | 15 | $51.78 | |
| 82248 | <1% | 13 | $36.05 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 41 | $29.45 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 374 | $10.15 |
| J2704 | Injection, propofol, 10 mg | <1% | 261 | $8.40 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 51 | $0.41 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 806 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 767 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 116 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 44 | $0.00 |
| 91300 | 0% | 552 | $0.00 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 0% | 13 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJORDAN, MONICA (DIRECTOR OF REIMBURSEMENT)
| Provider | Location | Paid |
|---|---|---|
| University of Miami Hospital and Clinics | Miami, FL | $62.12M |
| Gulf Health Hospitals, INC. | Fairhope, AL | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.